Where The Money Goes: Amorphous Dispersion Manufacturing

KinetiSol™ lowers modeled annual cost of goods from $20 million to $12 million, eliminates organic solvents and three processing steps, and cuts dispersion production time by nearly half. These findings anchor AustinPx’s comparison of KinetiSol and spray drying for manufacturing an oral drug formulated as an amorphous solid dispersion.
The case study examines where manufacturing costs accumulate, including solvent handling, nitrogen requirements, secondary drying, energy use and downstream processing. It also considers how early formulation decisions influence technology transfers, scale-up requirements and time to market, alongside opportunities for intellectual property generation and greater lifetime product value.
Explore the full analysis to see how evaluating KinetiSol early can improve manufacturing economics from development through commercial supply.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.